Coherus Oncology (CHRS) Inventory Average (2019 - 2026)
Coherus Oncology (CHRS) posted Inventory Average of $4.0 million for Q1 2026, up 53.2% sequentially from $2.6 million in Q4 2025, and up 3.52% YoY from $3.9 million in Q1 2025.
Coherus Oncology (CHRS) Inventory Average (2019 - 2026) Analysis & Trends
Coherus Oncology has reported Inventory Average for 8 years, with the latest figure at $4.0 million in Q1 2026.
- Quarterly Inventory Average rose 3.52% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (up 3.52% YoY) and the FY2025 annual result came in at $3.7 million, down 88.96% from the prior year.
- Inventory Average grew to $4.0 million in Q1 2026 per CHRS's latest filing, from $2.6 million in the prior quarter.
- Over five years, Inventory Average peaked at $65.4 million in Q3 2023 and troughed at $2.6 million in Q4 2025.
- A 5-year average of $34.6 million and a median of $34.3 million in 2022 frame the typical range for Inventory Average.
- The sharpest annual moves came in 2023 and 2025: Inventory Average soared 119.92% in 2023, then plunged 94.02% in 2025.
- Over 5 years, Inventory Average stood at $33.3 million in 2022, then surged by 94.54% to $64.7 million in 2023, then sank by 59.93% to $25.9 million in 2024, then sank by 89.93% to $2.6 million in 2025, then jumped by 53.2% to $4.0 million in 2026.
- According to Business Quant data, Inventory Average over the past three periods registered $4.0 million, $2.6 million, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn | 3.09 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn | 213.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 707.10 Mn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 90.57 Mn |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn | 196.36 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 137.65 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | - |
| 10 | Coherus Oncology | 213.00 Mn | 107.69 Mn | 10.07 Mn | 5.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.25 Mn |
| Mar 31, 2026 | 4.00 Mn |
| Dec 31, 2025 | 2.61 Mn |
| Sep 30, 2025 | 3.28 Mn |
| Jun 30, 2025 | 4.02 Mn |
| Mar 31, 2025 | 3.86 Mn |
| Dec 31, 2024 | 25.92 Mn |
| Sep 30, 2024 | 54.90 Mn |
| Jun 30, 2024 | 62.07 Mn |
| Mar 31, 2024 | 62.29 Mn |
| Dec 31, 2023 | 64.69 Mn |
| Sep 30, 2023 | 65.39 Mn |
| Jun 30, 2023 | 56.70 Mn |
| Mar 31, 2023 | 44.10 Mn |
| Dec 31, 2022 | 33.26 Mn |
| Sep 30, 2022 | 29.73 Mn |
| Jun 30, 2022 | 34.34 Mn |
| Mar 31, 2022 | 37.29 Mn |
| Dec 31, 2021 | 37.61 Mn |
| Sep 30, 2021 | 38.63 Mn |